Daihan Pharmaceutical Co., Ltd.

As of March 31, 2026, Daihan Pharmaceutical Co., Ltd. carries a market capitalization of 166.70B, placing it among publicly traded companies globally. Its enterprise value stands at 68.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Daihan Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 18, 2026.

As of March 31, 2026, Daihan Pharmaceutical Co., Ltd. has 5.88M shares outstanding.

As of March 31, 2026, Daihan Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 6.18. The price-to-sales ratio is 0.79, and the price-to-book ratio stands at 0.55.

As of March 31, 2026, Daihan Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 1.69 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 2.28 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Daihan Pharmaceutical Co., Ltd. trades at an EV/FCF ratio of 21.78, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 68.09B versus a market cap of 166.70B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Daihan Pharmaceutical Co., Ltd. maintains a current ratio of 3.61, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.02, indicating conservative leverage, while an interest coverage ratio of 16,212.81 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Daihan Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 9.31, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.49 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.89, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.31, useful for judging operating efficiency across full business cycles. The company generates approximately 299.49M in revenue per employee across its workforce of 706.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.55 indicates how many times Daihan Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Daihan Pharmaceutical Co., Ltd. recorded 5.17B in income tax expense. That works out to an effective tax rate of 16.07, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 32.15B, leaving 26.98B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Daihan Pharmaceutical Co., Ltd.'s stock has declined approximately 14.24% over the past 52 weeks. The 50-day moving average sits at 26,374.00, while the 200-day moving average is 27,474.75.

Over the twelve months ended March 31, 2026, Daihan Pharmaceutical Co., Ltd. generated 211.44B in revenue and converted that into 26.98B in net income, yielding earnings per share of 4,588.16. EBITDA reached 40.31B, while operating income came in at 29.81B.

As of March 31, 2026, Daihan Pharmaceutical Co., Ltd. holds 98.66B in cash and equivalents against 48.40M in total debt, resulting in a net debt position of -47.15B. Total book value stands at 301.16B, with working capital of 121.06B providing operational flexibility.

Daihan Pharmaceutical Co., Ltd. produced 26.07B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -22.94B in capital expenditures, free cash flow totaled 3.12B - equivalent to 531.35 per share.

Over the twelve months ended March 31, 2026, Daihan Pharmaceutical Co., Ltd. posted a gross margin of 30.01, reflecting its pricing power and cost economics. The operating margin of 14.10 and net profit margin of 12.76 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Daihan Pharmaceutical Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.87, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.15, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Daihan Pharmaceutical Co., Ltd. shareholders.

Daihan Pharmaceutical Co., Ltd.'s most recent stock split took place on April 29, 2002 with a 1:10 split ratio.

As of March 31, 2026, Daihan Pharmaceutical Co., Ltd. has an Altman Z-Score of 4.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.